Jaume Mora

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11496/publications.pdf

Version: 2024-02-01

170 papers	17,895 citations	44069 48 h-index	14759 127 g-index
173 all docs	173 docs citations	173 times ranked	27827 citing authors

#	Article	IF	Citations
1	Outpatient administration of naxitamab in combination with granulocyteâ€macrophage colonyâ€stimulating factor in patients with refractory and/or relapsed highâ€risk neuroblastoma: Management of adverse events. Cancer Reports, 2023, 6, e1627.	1.4	9
2	SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas. Journal of Controlled Release, 2022, 342, 81-92.	9.9	12
3	Identification of immunosuppressive factors in retinoblastoma cell secretomes and aqueous humor from patients. Journal of Pathology, 2022, , .	4.5	3
4	Selective histone methyltransferase G9a inhibition reduces metastatic development of Ewing sarcoma through the epigenetic regulation of NEU1. Oncogene, 2022, 41, 2638-2650.	5.9	10
5	How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de DÃ©u in Barcelona, Spain. ESMO Open, 2022, 7, 100462.	4.5	5
6	AC-265347 Inhibits Neuroblastoma Tumor Growth by Induction of Differentiation without Causing Hypocalcemia. International Journal of Molecular Sciences, 2022, 23, 4323.	4.1	1
7	Autologous Stem-Cell Transplantation for High-Risk Neuroblastoma: Historical and Critical Review. Cancers, 2022, 14, 2572.	3.7	7
8	The onset of PI3Kâ€related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib. EMBO Molecular Medicine, 2022, 14, .	6.9	19
9	MIF/CXCR4 signaling axis contributes to survival, invasion, and drug resistance of metastatic neuroblastoma cells in the bone marrow microenvironment. BMC Cancer, 2022, 22, .	2.6	5
10	WT1-Mutant Wilms Tumor Progression Is Associated With Diverting Clonal Mutations of CTNNB1. Journal of Pediatric Hematology/Oncology, 2021, 43, e180-e183.	0.6	4
11	Functional Common and Rare ERBB2 Germline Variants Cooperate in Familial and Sporadic Cancer Susceptibility. Cancer Prevention Research, 2021, 14, 441-454.	1.5	0
12	Recurrent Somatic Chromosomal Abnormalities in Relapsed Extraocular Retinoblastoma. Cancers, 2021, 13, 673.	3.7	9
13	Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma. Cancers, 2021, 13, 1264.	3.7	7
14	The transcriptional landscape of Shh medulloblastoma. Nature Communications, 2021, 12, 1749.	12.8	47
15	Prognostic value of patientâ€derived xenograft engraftment in pediatric sarcomas. Journal of Pathology: Clinical Research, 2021, 7, 338-349.	3.0	10
16	Clinicopathologic and molecular analysis of embryonal rhabdomyosarcoma of the genitourinary tract: evidence for a distinct DICER1-associated subgroup. Modern Pathology, 2021, 34, 1558-1569.	5.5	28
17	GEIS 39: Phase II trial of nabpaclitaxel for the treatment of patient with multiply relapsed/refractory desmoplastic small round cell tumor (DSRCT) and Ewing sarcoma (EwS).. Journal of Clinical Oncology, 2021, 39, 11529-11529.	1.6	1
18	Naxitamab combined with granulocyteâ€macrophage colonyâ€stimulating factor as consolidation for highâ€risk neuroblastoma patients in complete remission. Pediatric Blood and Cancer, 2021, 68, e29121.	1.5	21

#	Article	IF	Citations
19	Selective inhibition of HDAC6 regulates expression of the oncogenic driver EWSR1-FLI1 through the EWSR1 promoter in Ewing sarcoma. Oncogene, 2021, 40, 5843-5853.	5.9	10
20	Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathologica, 2021, 142, 859-871.	7.7	34
21	A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression. Nature Communications, 2021, 12, 5578.	12.8	45
22	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	12.8	237
23	Comprehensive Biology and Genetics Compendium of Wilms Tumor Cell Lines with Different WT1 Mutations. Cancers, 2021, 13, 60.	3.7	10
24	Correspondence on "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Martinez Sanz et al. , 2021, 9, e003751.		2
25	In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells. Nature Communications, 2020, 11, 5060.	12.8	60
26	LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma. Cell Reports, 2020, 30, 4567-4583.e5.	6.4	20
27	RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis. Science Advances, 2020, 6, .	10.3	24
28	The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies. Frontiers in Pharmacology, 2020, 11, 575009.	3.5	17
29	Treatment-driven selection of chemoresistant Ewing sarcoma tumors with limited drug distribution. Journal of Controlled Release, 2020, 324, 440-449.	9.9	7
30	Nivolumab in paediatric cancer: children are not little adults. Lancet Oncology, The, 2020, 21, 474-476.	10.7	7
31	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. Cell Reports Medicine, 2020, 1, 100038.	6.5	24
32	Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program. Acta Neuropathologica, 2019, 138, 1053-1074.	7.7	106
33	Parathyroid hormoneâ€like hormone plays a dual role in neuroblastoma depending on <scp>PTH</scp>1R expression. Molecular Oncology, 2019, 13, 1959-1975.	4.6	8
34	Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. Science Translational Medicine, 2019, 11, .	12.4	67
35	ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma. Communications Biology, 2019, 2, 156.	4.4	73
36	Editorial: Proceedings From the 4th Memorial Alicia Pueyo Workshop: â€œMoving Towards a Cure for Diffuse Intrinsic Pontine Gliomaâ€• Frontiers in Oncology, 2019, 9, 42.	2.8	0

#	Article	IF	Citations
37	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nature Medicine, 2019, 25, 1839-1842.	30.7	122
38	A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma. Clinical Cancer Research, 2019, 25, 1343-1357.	7.0	69
39	Preclinical Efficacy of Endoglin-Targeting Antibodyâ€“Drug Conjugates for the Treatment of Ewing Sarcoma. Clinical Cancer Research, 2019, 25, 2228-2240.	7.0	44
40	Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Preliminary results of HITS pilot/phase II study.. Journal of Clinical Oncology, 2019, 37, 10025-10025.	1.6	6
41	Glucosylated nanomicelles target glucose-avid pediatric patient-derived sarcomas. Journal of Controlled Release, 2018, 276, 59-71.	9.9	27
42	Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science, 2018, 360, 331-335.	12.6	461
43	EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma. International Journal of Cancer, 2018, 143, 1188-1201.	5.1	35
44	A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma. Clinical Cancer Research, 2018, 24, 1355-1363.	7.0	24
45	EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. Cancer Cell, 2018, 33, 202-216.e6.	16.8	116
46	DNA methylation-based reclassification of olfactory neuroblastoma. Acta Neuropathologica, 2018, 136, 255-271.	7.7	59
47	Upfront Nephrectomy for the Treatment of Wilms Tumor: Outcomes and Predictors of Complications. Journal of Child Science, 2018, 08, e21-e26.	0.2	1
48	Chemotherapy and terminal skeletal muscle differentiation in <scp>WT</scp>1â€mutant Wilms tumors. Cancer Medicine, 2018, 7, 1359-1368.	2.8	11
49	NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL. Leukemia, 2018, 32, 633-644.	7.2	35
50	Treatment of childhood astrocytomas with irinotecan and cisplatin. Clinical and Translational Oncology, 2018, 20, 500-507.	2.4	3
51	Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with highâ€risk neuroblastoma: A case series. Pediatric Blood and Cancer, 2018, 65, e26732.	1.5	21
52	Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. Acta Neuropathologica, 2018, 136, 239-253.	7.7	118
53	Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells. Nature Medicine, 2018, 24, 1204-1215.	30.7	133
54	Protocolo de un dÃa vs protocolo de dos dÃas de adquisiciÃ³n mediante gammagrafÃa con leucocitos marcados in vitro para el diagnÃ³stico de infecciÃ³n osteoarticular. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 277-284.	0.0	3

#	Article	IF	Citations
55	Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma. Frontiers in Oncology, 2018, 8, 127.	2.8	31
56	Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response. Molecular Cancer Therapeutics, 2018, 17, 1902-1916.	4.1	48
57	Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica, 2018, 136, 227-237.	7.7	86
58	Riskâ€"benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. Future Oncology, 2018, 14, 2663-2676.	2.4	105
59	Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. Acta Neuropathologica, 2018, 136, 327-337.	7.7	104
60	Tissue Compatibility of SNâ€38â€Loaded Anticancer Nanofiber Matrices. Advanced Healthcare Materials, 2018, 7, e1800255.	7.6	5
61	The combination of epigenetic drugs SAHA and HCI-2509 synergistically inhibits EWS-FLI1 and tumor growth in Ewing sarcoma. Oncotarget, 2018, 9, 31397-31410.	1.8	27
62	EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nature Medicine, 2017, 23, 483-492.	30.7	392
63	Tissue sampling in diffuse intrinsic pontine glioma (DIPG) at progression. Pediatric Blood and Cancer, 2017, 64, e26492.	1.5	0
64	Second re-irradiation for DIPG progression, re-considering â€œold strategiesâ€•with new approaches. Child's Nervous System, 2017, 33, 849-852.	1.1	14
65	Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8. Journal of Controlled Release, 2017, 255, 108-119.	9.9	35
66	Genetic variants in the promoter region of the calciumâ€sensing receptor gene are associated with its downâ€regulation in neuroblastic tumors. Molecular Carcinogenesis, 2017, 56, 1281-1289.	2.7	11
67	Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell, 2017, 31, 737-754.e6.	16.8	836
68	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer Cell, 2017, 32, 520-537.e5.	16.8	716
69	Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS). Annals of Oncology, 2017, 28, 2994-2999.	1.2	45
70	Increased delivery of chemotherapy to the vitreous by inhibition of the blood-retinal barrier. Journal of Controlled Release, 2017, 264, 34-44.	9.9	11
71	DNA Methylomes Reveal Biological Networks Involved in Human Eye Development, Functions and Associated Disorders. Scientific Reports, 2017, 7, 11762.	3.3	44
72	The whole-genome landscape of medulloblastoma subtypes. Nature, 2017, 547, 311-317.	27.8	787

#	Article	IF	Citations
73	GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS). British Journal of Cancer, 2017, 117, 767-774.	6.4	17
74	DNA methylation profiling identifies PTRF/Cavin-1 as a novel tumor suppressor in Ewing sarcoma when co-expressed with caveolin-1. Cancer Letters, 2017, 386, 196-207.	7.2	25
75	Neural crest derived progenitor cells contribute to tumor stroma and aggressiveness in stage 4/M neuroblastoma. Oncotarget, 2017, 8, 89775-89792.	1.8	4
76	The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget, 2016, 7, 8613-8624.	1.8	55
77	Establishment of a Conditionally Immortalized Wilms Tumor Cell Line with a Homozygous WT1 Deletion within a Heterozygous 11p13 Deletion and UPD Limited to 11p15. PLoS ONE, 2016, 11, e0155561.	2.5	10
78	Preclinical platform of retinoblastoma xenografts recapitulating human disease and molecular markers of dissemination. Cancer Letters, 2016, 380, 10-19.	7.2	22
79	Safety of bevacizumab in patients younger than 4 years of age. Clinical and Translational Oncology, 2016, 18, 464-468.	2.4	11
80	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology, 2016, 34, 2468-2477.	1.6	160
81	Use of 3D Prototypes for Complex Surgical Oncologic Cases. World Journal of Surgery, 2016, 40, 889-894.	1.6	49
82	SN-38-loaded nanofiber matrices for local control of pediatric solid tumors after subtotal resection surgery. Biomaterials, 2016, 79, 69-78.	11.4	40
83	Hipoestesia mentoniana como manifestaciÃ³n de metÃ¡stasis mandibular diagnosticada en la gammagrafÃa Ã³sea. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2016, 35, 34-37.	0.0	0
84	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell, 2016, 29, 379-393.	16.8	438
85	Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma. Expert Review of Clinical Pharmacology, 2016, 9, 647-653.	3.1	39
86	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology, The, 2016, 17, 484-495.	10.7	274
87	Landscape of early clinical trials for childhood and adolescence cancer in Spain. Clinical and Translational Oncology, 2016, 18, 708-713.	2.4	4
88	RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-Î²B pathway, independently of the fusion oncoprotein. Oncotarget, 2016, 7, 46283-46300.	1.8	12
89	Cinacalcet inhibits neuroblastoma tumor growth and upregulates cancer-testis antigens. Oncotarget, 2016, 7, 16112-16129.	1.8	19
90	Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression. Oncotarget, 2016, 7, 21840-21852.	1.8	85

#	Article	IF	Citations
91	The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin. Oncotarget, 2015, 6, 18875-18890.	1.8	74
92	Results of induction chemotherapy in children older than 18Âmonths with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7). Clinical and Translational Oncology, 2015, 17, 521-529.	2.4	14
93	Results of the survey about the use of the SPECT-CT in bone pathology in Spain during 2012. Medecine Nucleaire, 2015, 39, 444-449.	0.2	0
94	DNA methylation fingerprint of neuroblastoma reveals new biological and clinical insights. Epigenomics, 2015, 7, 1137-1153.	2.1	40
95	Combined Microdialysis-Tumor Homogenate Method for the Study of the Steady State Compartmental Distribution of a Hydrophobic Anticancer Drug in Patient-Derived Xenografts. Pharmaceutical Research, 2015, 32, 2889-2900.	3.5	11
96	Desmoplastic small round cell tumor 20 years after its discovery. Future Oncology, 2015, 11, 1071-1081.	2.4	39
97	Orphan drugs revisited: costâ€“effectiveness analysis of the addition of mifamurtide to the conventional treatment of osteosarcoma. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 331-340.	1.4	7
98	Low-grade gliomas in children: single institutional experience in 198 cases. Child's Nervous System, 2015, 31, 1447-1459.	1.1	10
99	Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5564-73.	7.1	355
100	Simultaneous <scp>KIT</scp> mutation and succinate dehydrogenase (<scp>SDH</scp>) deficiency in a patient with a gastrointestinal stromal tumour and Carneyâ€Stratakis syndrome: a case report. Histopathology, 2014, 65, 712-717.	2.9	7
101	The Genomic Landscape of Pediatric Ewing Sarcoma. Cancer Discovery, 2014, 4, 1326-1341.	9.4	415
102	Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors. Cancer Discovery, 2014, 4, 216-231.	9.4	596
103	Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nature Genetics, 2014, 46, 457-461.	21.4	423
104	Cytogenetic Prognostication Within Medulloblastoma Subgroups. Journal of Clinical Oncology, 2014, 32, 886-896.	1.6	263
105	Intraâ€arterial chemotherapy for retinoblastoma. Challenges of a prospective study. Acta Ophthalmologica, 2014, 92, 209-215.	1.1	27
106	Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis. Journal of Clinical Investigation, 2014, 124, 5275-5290.	8.2	81
107	Caveolin-1 is down-regulated in alveolar rhabdomyosarcomas and negatively regulates tumor growth. Oncotarget, 2014, 5, 9744-9755.	1.8	19
108	Brain stem tumors in children and adolescents: single institutional experience. Child's Nervous System, 2013, 29, 1321-1331.	1.1	28

#	Article	IF	Citations
109	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncology, The, 2013, 14, 1200-1207.	10.7	307
110	The calcium-sensing receptor is silenced by genetic and epigenetic mechanisms in unfavorable neuroblastomas and its reactivation induces ERK1/2-dependent apoptosis. Carcinogenesis, 2013, 34, 268-276.	2.8	35
111	Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature, 2013, 499, 214-218.	27.8	4,761
112	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathologica, 2013, 126, 917-929.	7.7	146
113	Genetics of pheochromocytoma and paraganglioma in Spanish pediatric patients. Endocrine-Related Cancer, 2013, 20, L1-L6.	3.1	44
114	Burkitt's lymphoma treatment in a rural hospital in Sierra Leone. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2013, 107, 653-659.	1.8	5
115	Polymorphisms in the Calcium-Sensing Receptor Gene Are Associated with Clinical Outcome of Neuroblastoma. PLoS ONE, 2013, 8, e59762.	2.5	13
116	EphA2-Induced Angiogenesis in Ewing Sarcoma Cells Works through bFGF Production and Is Dependent on Caveolin-1. PLoS ONE, 2013, 8, e71449.	2.5	34
117	What is a pediatric tumor?. Clinical Oncology in Adolescents and Young Adults, 2012, , 7.	0.8	6
118	A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma. Clinical Cancer Research, 2012, 18, 2012-2023.	7.0	59
119	DNA Hypomethylation Affects Cancer-Related Biological Functions and Genes Relevant in Neuroblastoma Pathogenesis. PLoS ONE, 2012, 7, e48401.	2.5	31
120	Activated growth signaling pathway expression in Ewing sarcoma and clinical outcome. Pediatric Blood and Cancer, 2012, 58, 532-538.	1.5	26
121	A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. Journal of Clinical Investigation, 2012, 122, 2983-2988.	8.2	347
122	Identification of tumoral glial precursor cells in neuroblastoma. Cancer Letters, 2011, 312, 73-81.	7.2	9
123	Treatment of Ewing sarcoma family of tumors with a modified P6 protocol in children and adolescents. Pediatric Blood and Cancer, 2011, 57, 69-75.	1.5	12
124	Antiangiogenic treatment as a preâ€operative management of alveolar softâ€part sarcoma. Pediatric Blood and Cancer, 2011, 57, 1071-1073.	1.5	20
125	Axenfeldâ€“Rieger ocular anomaly and retinoblastoma caused by constitutional chromosome 13q deletion. Pediatric Blood and Cancer, 2010, 54, 480-482.	1.5	6
126	Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm. Human Molecular Genetics, 2010, 19, 1651-1668.	2.9	66

#	Article	IF	Citations
127	Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. Molecular Cancer, 2010, 9, 277.	19.2	57
128	Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature. Clinical Cancer Research, 2010, 16, 1532-1541.	7.0	86
129	Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma. BMC Cancer, 2009, 9, 44.	2.6	26
130	The calciumâ€sensing receptor and parathyroid hormoneâ€related protein are expressed in differentiated, favorable neuroblastic tumors. Cancer, 2009, 115, 2792-2803.	4.1	23
131	Treatment of disseminated paraganglioma with gemcitabine and docetaxel. Pediatric Blood and Cancer, 2009, 53, 663-665.	1.5	10
132	Comprehensive characterization of neuroblastoma cell line subtypes reveals bilineage potential similar to neural crest stem cells. BMC Developmental Biology, 2009, 9, 12.	2.1	54
133	Use of angioembolization as an effective technique for the management of pediatric solid tumors. Journal of Pediatric Surgery, 2009, 44, 1848-1855.	1.6	16
134	Treatment of Relapsed/Refractory Pediatric Sarcomas With Gemcitabine and Docetaxel. Journal of Pediatric Hematology/Oncology, 2009, 31, 723-729.	0.6	73
135	Differential expression of genes mapping to recurrently abnormal chromosomal regions characterize neuroblastic tumours with distinct ploidy status. BMC Medical Genomics, 2008, 1, 36.	1.5	9
136	Fibrolamellar Hepatocellular Carcinoma in an Infant and Literature Review. Journal of Pediatric Hematology/Oncology, 2008, 30, 968-971.	0.6	9
137	Successful treatment of childhood intramedullary spinal cord astrocytomas with irinotecan and cisplatin. Neuro-Oncology, 2007, 9, 39-46.	1.2	24
138	Primary Ewing sarcoma of the tentorium presenting with intracranial hemorrhage in a child. Journal of Neurosurgery: Pediatrics, 2007, 107, 411-415.	1.3	27
139	Different CTNNB1 mutations as molecular genetic proof for the independent origin of four Wilms tumours in a patient with a novel germ line WT1 mutation. Journal of Medical Genetics, 2007, 44, 393-396.	3.2	25
140	Comprehensive analysis of tumoral DNA content reveals clonal ploidy heterogeneity as a marker with prognostic significance in locoregional neuroblastoma. Genes Chromosomes and Cancer, 2007, 46, 385-396.	2.8	10
141	Molecular pathways linking the pheochromocytoma susceptibility genesâ€"response. Pediatric Blood and Cancer, 2007, 49, 1052-1053.	1.5	0
142	High TGFÎ²-Smad Activity Confers Poor Prognosis in Glioma Patients and Promotes Cell Proliferation Depending on the Methylation of the PDGF-B Gene. Cancer Cell, 2007, 11, 147-160.	16.8	446
143	Epstein-Barr virus related opsoclonus-myoclonus-ataxia does not rule out the presence of occult neuroblastic tumors. Pediatric Blood and Cancer, 2006, 47, 964-967.	1.5	17
144	Pediatric paraganglioma: An early manifestation of an adult disease secondary to germline mutations. Pediatric Blood and Cancer, 2006, 47, 785-789.	1.5	20

#	Article	IF	Citations
145	Epithelioid sarcoma with SYT-SSX1 fusion gene expression: molecular and cytogenetic analysis. Cancer Genetics and Cytogenetics, 2005, 162, 50-56.	1.0	11
146	Primitive hematopoietic malignant neoplasm presenting as a CD43-positive, small round, blue-cell tumor in an infant. Pediatric Blood and Cancer, 2005, 45, 865-866.	1.5	3
147	EMP3, a Myelin-Related Gene Located in the Critical 19q13.3 Region, Is Epigenetically Silenced and Exhibits Features of a Candidate Tumor Suppressor in Glioma and Neuroblastoma. Cancer Research, 2005, 65, 2565-2571.	0.9	154
148	Comprehensive analysis of the 9p21 region in neuroblastoma suggests a role for genes mapping to 9p21â€“23 in the biology of favourable stage 4 tumours. British Journal of Cancer, 2004, 91, 1112-1118.	6.4	12
149	Positional gene expression analysis identifies 12q overexpression and amplification in a subset of neuroblastomas. Cancer Genetics and Cytogenetics, 2004, 154, 131-137.	1.0	30
150	Origin of neuroblastic tumors: clues for future therapeutics. Expert Review of Molecular Diagnostics, 2004, 4, 293-302.	3.1	25
151	Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol. Cancer, 2003, 98, 1283-1291.	4.1	67
152	Evolving significance of prognostic markers associated with new treatment strategies in neuroblastoma. Cancer Letters, 2003, 197, 119-124.	7.2	25
153	Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma. Cancer Research, 2003, 63, 4538-46.	0.9	65
154	Evolving significance of prognostic markers associated with treatment improvement in patients with Stage 4 neuroblastoma. Cancer, 2002, 94, 2756-2765.	4.1	28
155	Novel regions of allelic imbalance identified by genome-wide analysis of neuroblastoma. Cancer Research, 2002, 62, 1761-7.	0.9	17
156	Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease. Cancer, 2001, 91, 435-442.	4.1	23
157	N7: A novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Medical and Pediatric Oncology, 2001, 36, 227-230.	1.0	114
158	Genetic heterogeneity and clonal evolution in neuroblastoma. British Journal of Cancer, 2001, 85, 182-189.	6.4	32
159	Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature, 2001, 409, 207-211.	27.8	901
160	Molecular Genetics of Neuroblastoma and the Implications for Clinical Management: A Review of the MSKCC Experience. Oncologist, 2001, 6, 263-268.	3.7	15
161	N7: A novel multiâ€modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Medical and Pediatric Oncology, 2001, 36, 227-230.	1.0	1
162	Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease. Cancer, 2001, 91, 435-42.	4.1	4

#	Article	IF	Citations
163	Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma. Clinical Cancer Research, 2001, 7, 1358-61.	7.0	42
164	Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell. Cancer Research, 2001, 61, 6892-8.	0.9	79
165	Large cell non-Hodgkin lymphoma of childhood. , 2000, 88, 186-197.		49
166	Spontaneous remission of congenital acute nonlymphoblastic leukemia with normal karyotype in twins. Medical and Pediatric Oncology, 2000, 35, 110-113.	1.0	23
167	Laser-capture microdissected Schwannian and neuroblastic cells in stage 4 neuroblastomas have the same genetic alterations. Medical and Pediatric Oncology, 2000, 35, 534-537.	1.0	11
168	Clinical Categories of Neuroblastoma Are Associated with Different Patterns of Loss of Heterozygosity on Chromosome Arm 1p. Journal of Molecular Diagnostics, 2000, 2, 37-46.	2.8	46
169	Primary epidural non-Hodgkin lymphoma: Spinal cord compression syndrome as the initial form of presentation in childhood non-Hodgkin lymphoma. , 1999, 32, 102-105.		35
170	Listeriosis in pediatric oncology patients. , 1998, 83, 817-820.		13